Apellis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03753U1060
DENNA SYMBOL ÄR INTE LÄNGRE AKTIV

SecurityAPLS / Apellis Pharmaceuticals, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership6,206,681 shares
Latest Disclosed Value $ 249,694,778
UBS Group AG ownership in APLS / Apellis Pharmaceuticals, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 6,206,681 shares of Apellis Pharmaceuticals, Inc. (US:APLS) valued at $249,694,777 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 4,186,222 shares of Apellis Pharmaceuticals, Inc.. This represents a change in shares of 48.26% during the quarter. The current value of the position is $254,660,121 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (APLS) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

APLS / Apellis Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 6,206,681 2,020,459 48.26 249,695 137.45 0.0070
2026-01-29 2025-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 4,186,222 756,317 22.05 105,158 35.48 0.0171
2025-11-13 2025-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 3,429,905 -1,305,406 -27.57 77,619 -5.31 0.0122
2025-08-14 2025-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 4,735,311 1,463,117 44.71 81,968 14.54 0.0142
2025-05-13 2025-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 3,272,194 685,455 26.50 71,563 -13.30 0.0132
2025-02-14 2024-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 2,586,739 2,272,055 722.01 82,543 809.55 0.0153
2024-11-14 2024-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 314,684 42,287 15.52 9,075 -13.15 0.0020
2024-08-14 2024-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 272,397 161,105 144.76 10,449 59.75 0.0026
2024-05-13 2024-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 111,292 16,258 17.11 6,542 15.00 0.0016
2024-02-09 2023-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 95,034 91,168 2,358.20 5,689 3,769.39 0.0017
2023-11-09 2023-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 3,866 -92,589 -95.99 147 -98.33 0.0001
2023-08-11 2023-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 96,455 -7,909 -7.58 8,787 27.66 0.0030
2023-05-12 2023-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 104,364 -27,533 -20.87 6,884 0.92 0.0025
2023-02-08 2022-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 131,897 117,258 801.00 6,820 582.00 0.0025
2022-11-10 2022-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 14,639 -57,484 -79.70 1,000 -69.34 0.0004
2022-08-10 2022-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 72,123 -42,526 -37.09 3,262 -44.00 0.0013
2022-05-16 2022-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 114,649 5,262 4.81 5,825 12.63 0.0019
2022-02-14 2021-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 109,387 -87,495 -44.44 5,172 -20.30 0.0015
2021-11-15 2021-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 196,882 140,763 250.83 6,489 82.94 0.0020
2021-08-13 2021-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 56,119 44,425 379.90 3,547 606.57 0.0011
2021-05-12 2021-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 11,694 10,663 1,034.24 502 750.85 0.0002
2021-02-11 2020-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 1,031 738 251.88 59 555.56 0.0000
2020-11-12 2020-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 293 -2,527 -89.61 9 -90.22 0.0000
2020-07-31 2020-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 2,820 -10,118 -78.20 92 -73.49 0.0000
2020-05-01 2020-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 12,938 -5,933 -31.44 347 -39.97 0.0002
2020-02-14 2019-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 18,871 -11,981 -38.83 578 -22.21 0.0002
2019-11-14 2019-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 30,852 -15,674 -33.69 743 -36.98 0.0003
2019-08-14 2019-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 46,526 37,175 397.55 1,179 547.80 0.0005
2019-05-14 2019-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 9,351 -54,828 -85.43 182 -78.51 0.0001
2019-02-14 2018-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 64,179 38,146 146.53 847 82.94 0.0004
2018-11-14 2018-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 26,033 19,544 301.19 463 223.78 0.0002
2018-08-14 2018-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 6,489 1,298 25.00 143 24.35 0.0001
2018-05-15 2018-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 5,191 1,288 33.00 115 35.29 0.0000
2018-02-14 2017-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 3,903 3,903 85 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-02-08 2022-12-31 13F APELLIS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-11-10 2022-09-30 13F APELLIS PHARMACEUTICALS COM Call 15,500 1,059 n/a n/a n/a
2020-05-01 2020-03-31 13F APELLIS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-02-14 2019-12-31 13F APELLIS PHARMACEUTICALS COM Call 9,300 285 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-02-14 2024-12-31 13F APELLIS PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-14 2024-09-30 13F APELLIS PHARMACEUTICALS COM Put 13,500 0.00 389 -24.76 n/a n/a n/a
2024-08-14 2024-06-30 13F APELLIS PHARMACEUTICALS COM Put 13,500 518 n/a n/a n/a
2023-11-09 2023-09-30 13F APELLIS PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-11 2023-06-30 13F APELLIS PHARMACEUTICALS COM Put 49,900 4,546 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.